Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie

Executive Summary

Novartis expected to give Joe Jimenez a good farewell gift; AbbVie says it is not planning major M&A to focus on risankizumab and upadacitinib, but Celgene is on the hunt for deals – will Juno be its next big buy?

Advertisement

Related Content

PTAB Clears Path For Earlier Generic Zytiga Launch
Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
Should Celgene Succumb To The Charms Of Juno?
Novartis' Cosentyx Goes Head-To-Head With Humira
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Novartis' Kisqali Impresses In Premenopausal Breast Cancer As Market Crowds
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene Plots Blockbuster Course For Ozanimod
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel